Our focus has been on the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neuro-inflammatory disorders. We are not currently advancing the development of our products and are focused on exploring strategic options that may include a sale of the Company, a merger, an acquisition by us, or other strategic alternative.